Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 8.1 Exhibit 8.1
- 23.2 Exhibit 23.2
- 23.3 Exhibit 23.3
- 99.2 Exhibit 99.2
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- 99.8 Exhibit 99.8
- 99.9 Exhibit 99.9
- 99.10 Exhibit 99.10
- 99.11 Exhibit 99.11
- 99.12 Exhibit 99.12
- EX-FILING FEES Filing Fees Table
Associated filings
- 2022 Q2 10-Q Quarterly report
- 4 May 22 8-K Entry into a Material Definitive Agreement
- 4 May 22 425 Business combination disclosure
- 19 Apr 22 EFFECT Notice of effectiveness
- 18 Apr 22 424B3 Prospectus supplement
- 14 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 5 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 18 Mar 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
22 Feb 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 11 Jan 22 S-4 Registration of securities issued in business combination transactions
AZPN similar filings
Filing view
External links
Exhibit 99.12
Consent to be Named as a Director Nominee
In connection with the filing by Emersub CX, Inc. (“New AspenTech”) of the Registration Statement on Form S-4, and in all subsequent amendments and post-effective amendments or supplements thereto, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of New AspenTech in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: February 22, 2022
/s/ Patrick M. Antkowiak | |
Patrick M. Antkowiak |